RNA fusions involving CD28 are rare in peripheral T-cell lymphomas and concentrate mainly in those derived from follicular helper T cells

Peripheral T-cell lymphomas (PTCL) comprise usually aggressive neoplasms of mature T cells with a heterogeneous molecular background. Over the past years, several genomic studies stemming from different research groups have shown evidence that mutation-induced activation of the T-cell receptor (TCR

• Publication year

  2018

• Venue

  Haematologica

• Publication date

  2018-08-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.3324/haematol.2017.186767PMID 29545337PMCID PMC6068042
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Integrative clinicopathological and molecular analyses of angioimmunoblastic T-cell lymphoma and other nodal lymphomas of follicular helper T-cell origin

  2017cited by this paper
• Activating mutations in genes related to TCR signaling in angioimmunoblastic and other follicular helper T-cell-derived lymphomas.

  2016cited by this paper
• Recurrent activating mutations of CD28 in peripheral T-cell lymphomas

  2016cited by this paper
• Frequent CTLA4-CD28 gene fusion in diverse types of T-cell lymphoma

  2016cited by this paper
• Comment on: Frequent CTLA4-CD28 gene fusion in diverse types of T-cell lymphoma, by Yoo et al.

  2016cited by this paper
• Angioimmunoblastic T-cell lymphoma is the most common T-cell lymphoma in two distinct French information data sets

  2015cited by this paper
• Genomic analysis of mycosis fungoides and Sézary syndrome identifies recurrent alterations in TNFR2

  2015cited by this paper
• Integrated molecular analysis of adult T cell leukemia/lymphoma

  2015cited by this paper
• Genomic profiling of Sézary syndrome identifies alterations of key T cell signaling and differentiation genes

  2015cited by this paper
• Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas

  2014cited by this paper
• Personalized treatment of Sézary syndrome by targeting a novel CTLA4:CD28 fusion

  2014cited by this paper
• Somatic RHOA mutation in angioimmunoblastic T cell lymphoma

  2014cited by this paper
• A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma

  2014cited by this paper
• Molecular mechanisms of T cell co-stimulation and co-inhibition

  2013cited by this paper
• Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters.

  2012cited by this paper

• Integrative Genomic and Transcriptomic Analysis Reveals Targetable Vulnerabilities in Angioimmunoblastic T‐Cell Lymphoma

  2025cites this paper
• Biological and Clinical Relevance of Genetic Alterations in Peripheral T-cell Lymphomas

  2025cites this paper
• A patient-derived T cell lymphoma biorepository uncovers pathogenetic mechanisms and host-related therapeutic vulnerabilities

  2025cites this paper
• Genome-epigenome crosstalk in T-cell lymphomas: from maps to mechanisms.

  2025cites this paper
• Advances in peripheral T cell lymphomas: pathogenesis, genetic landscapes and emerging therapeutic targets

  2024cites this paper
• Role of the crosstalk B:neoplastic T follicular helper (TFH) cells in the pathobiology of nodal TFH cell lymphomas.

  2024cites this paper
• New insights into the biology of T-cell lymphomas.

  2024cites this paper
• Precise diagnosis and treatment for peripheral T-cell lymphomas: From pathogenic mechanisms to innovative approaches

  2024cites this paper
• Therapeutic challenges in peripheral T-cell lymphoma

  2024cites this paper
• Pathobiology of nodal peripheral T-cell lymphomas: current understanding and future directions

  2023cites this paper
• Co-stimulatory and immune checkpoint molecules are important in the tumor microenvironment of Hodgkin-like adult T-cell leukemia/lymphoma

  2023cites this paper
• How molecular advances may improve the diagnosis and management of PTCL patients

  2023cites this paper
• Novel T Follicular Helper-like T-Cell Lymphoma Therapies: From Preclinical Evaluation to Clinical Reality

  2022cites this paper
• Nodal cytotoxic peripheral T-cell lymphoma occurs frequently in the clinical setting of immunodysregulation and is associated with recurrent epigenetic alterations

  2022cites this paper
• Detection of gene fusion transcripts in Peripheral T-cell Lymphoma using a multiplexed targeted sequencing assay.

  2021cites this paper
• The role of CD28 in adult T‐cell leukaemia/lymphoma

  2021cites this paper
• Comprehensive genomic analysis identifying heterogeneity in peripheral T‐cell lymphoma

  2021cites this paper
• Mechanisms of T‐cell Lymphomagenesis

  2021cites this paper
• Angioimmunoblastic T‐cell Lymphoma

  2021cites this paper
• Clinicopathological significance of CD28 overexpression in adult T‐cell leukemia/lymphoma

  2021cites this paper
• Tumor microenvironment of adult T-cell leukemia/lymphoma

  2021cites this paper
• Peripheral T cell lymphomas: from the bench to the clinic

  2020cites this paper
• Commentary on: clinical significance of CD28 gene-related activating alterations in adult T-cell leukaemia/lymphoma.

  2020cites this paper
• Clinical significance of CD28 gene‐related activating alterations in adult T‐cell leukaemia/lymphoma

  2020cites this paper
• Controversies in the Treatment of Peripheral T-cell Lymphoma

  2020cites this paper
• New preclinical models for angioimmunoblastic T-cell lymphoma: filling the GAP

  2020cites this paper
• Lymphoma Classification.

  2020cites this paper
• CD28 fusions: an opportunity for young ATL?

  2020cites this paper
• PD-1 Tumor Suppressor Signaling in T Cell Lymphomas.

  2019cites this paper
• Genomic landscape of young ATLL patients identifies frequent targetable CD28 fusions.

  2019cites this paper
• Approach to nodal-based T-cell lymphomas.

  2019cites this paper
• Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma.

  2019cites this paper
• New insights in the pathogenesis of T-cell lymphomas

  2018cites this paper
• Binding of RHOA G17V to p300 enhances its HAT activity: a new mechanism of epigenetic deregulation in TFH lymphoma

  1999cites this paper